CXCL10 production is enhanced in the setting of HIV and HBV co-infection in vitro and decreased with the addition of antiretroviral agents efavirenz or raltegravir. by Kasha P. Singh (9354307)

m⁵C modified sites C131 and C2017 positively regulate HBV replication. by Jiangpeng Feng (9287738)

Subjects:

Shoot-to-root translocation of GmNN1/FT2a regulates soybean nodulation. by Xinxin Li (281237)

IODVA1 inhibits lamellipodia and circular dorsal ruffle (CDR) formation in MDA-MB-231 cells and decreases Rac activation. by Anjelika Gasilina (8566296)

GSK343 decreased viability and proliferation in human neuroblastoma PDX cells. by Laura V. Bownes (10276762)

“…GSK343 treatment resulted in significantly decreased viability. (B) COA3 and COA6 (1.5 × 10³) cells were treated with increasing concentrations of GSK343 (0, 5, 15, 25 μM) for 24 hours and proliferation was measured using CellTiter^® assay. …”

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

“…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”

SARS-CoV-2 decreases excitatory synapses, while influenza A does not induce cell death in BCO. by Pinar Mesci (14053895)

Positional cloning of <i>qNN1</i> on chromosome 16. by Xinxin Li (281237)

Osr1 heterozygous mice experienced decreased bile acid synthesis in the liver. by Ernest C. Lynch (12769954)

“…Osr1 female mice had significantly increased gene expression of <i>Plin4</i> and <i>Plin5</i>. Data is presented as Mean±SD, N = 5; *p<0.05.…”

Significantly decreased adhesion to host cells by the Δ<i>tad123</i> mutant (A) and time-dependent recovery (B). by Tra-My Duong-Nu (7300970)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects: